Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received a grant of 28,145 RSUs, representing a $1 million target-value equity award. The RSUs are scheduled to vest over three years in three equal annual tranches starting April 1, 2026, with a two-year post-vest holding period on net after-tax shares. Following this grant, Beyer directly holds 28,145 RSUs tied to CONMED common stock, designed to align compensation with longer-term company performance.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting zero beneficial ownership of CONMED Corp common stock. The filing states 03/13/2026 and is signed on 03/26/2026. It explains an internal realignment on January 12, 2026 that caused separate reporting by Vanguard subsidiaries and business divisions. The filing lists 0% ownership and 0 shares, and states no single external person holds more than 5% of the class.
Lalomia Brent reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported that Executive VP RA, QA Brent Lalomia received a corrected grant of 17,198 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan. Each RSU represents one share of common stock, vesting 33% after one year, 33% after two years, and 34% after three years.
The filing explains that this amended Form 4 updates the originally reported 9,554 RSUs to include a special award of 7,644 additional RSUs, bringing the total grant to 17,198 units.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported an amended Form 4 showing that executive Matthew Schabacker, VP GM Advanced Surgical, received a corrected grant of 17,471 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan.
Each RSU represents a contingent right to one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. The amendment clarifies that this total includes a special award of 7,644 RSUs in addition to the originally reported 9,827 RSUs.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation granted General Counsel and Corporate Secretary Hollie K. Foust 18,563 restricted stock units (RSUs) under its 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% in the second year, and 34% in the third year. This Form 4/A amends a prior report to correct the grant amount, noting that a special award of 7,644 RSUs was added to the originally reported 10,919 RSUs to reach the total of 18,563 RSUs.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation’s Executive Vice President – HR, John D. Ferrell, reported a compensation-related grant of 16,926 restricted stock units (RSUs). The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years.
This amended Form 4 corrects the originally reported grant amount by reflecting an additional special award of 7,644 RSUs on top of the previously reported 9,282 RSUs, bringing the total to 16,926 RSUs tied to an equivalent number of common shares.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation executive Peter K. Shagory received a corrected equity award totaling 16,926 restricted stock units (RSUs). Each RSU represents a right to receive one share of CONMED common stock under the Company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. This Form 4/A amends the prior report to reflect that a special award of 7,644 RSUs was granted in addition to the originally reported 9,282 RSUs, for the total 16,926 RSUs now shown as held directly following the transaction.
CONMED Corporation reported that Andrew Moller, age 51, will become Interim Principal Financial Officer effective March 15, 2026. He currently serves as Vice President, Corporate Controller and has been the Company’s Principal Accounting Officer since April 2025.
Before joining CONMED in January 2025, Moller held senior finance roles at Smith & Nephew, including Global Controller and CFO Asia-Pacific, and previously worked at Stanley Black & Decker. The company states there are no related-party transactions or family relationships involving Moller and its directors, and his compensation arrangements are unchanged with this interim appointment.
CONMED Corp executive Brent Lalomia exercised restricted stock units and received additional common shares as compensation. On March 6, 2026, 75 RSUs converted into 75 shares of common stock, and 26 of those shares were withheld at a price of $39.90 per share to cover tax obligations. After these transactions, Lalomia directly held 915.057 shares of CONMED common stock. A footnote also clarifies that prior reported holdings have been adjusted to exclude 140 shares that were previously reported in error.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that executive Matthew Schabacker, VP GM Advanced Surgical, received equity awards consisting of 9,827 restricted stock units and options to purchase 11,646 shares of common stock. The RSUs generally vest over three years, while the stock options generally vest in equal parts over four years.